(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 February 2020 (20.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/035816 A1

(51) International Patent Classification:
A61K 47/60 (2017.01) *A61P 35/00* (2006.01)
A61K 47/64 (2017.01)

(21) International Application Number:
PCT/IB2019/056926

(22) International Filing Date:
15 August 2019 (15.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/719,314 17 August 2018 (17.08.2018) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **ASHFORD, Marianne**; AstraZeneca UK Limited, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **BALACHANDER, Srividya**; AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **OWEN, David**; StarPharma Pty Limited, 4-6 Southampton Crescent, Abbotsford, Victoria 3067 (AU). **PORTER, Christopher John Hamilton**; 200 Nelson Road, South Melbourne, Victoria 3205 (AU).

(74) Agent: **STORM, Peter**; ASTRAZENECA AB, SE-151-85, Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: CONJUGATES FOR USE IN METHODS OF TREATING CANCER

(57) Abstract: Disclosed are methods of treating cancer in a subject, comprising subcutaneously administering to the subject an effective amount of a dendrimer of formula (I): (I) and pharmaceutically acceptable salts thereof.



(I)

WO 2020/035816 A1